Metastatic pancreatic cancer has resisted nearly every advance in oncology of the past two decades. A phase 3 trial reported this year moved the number that matters.
Among 500 patients with previously treated metastatic pancreatic cancer, daraxonrasib extended median overall survival to 13.2 months compared with 6.7 months on standard chemotherapy. The results drew a standing ovation at the American Society of Clinical Oncology annual meeting and were published simultaneously in the New England Journal of Medicine.
